Mirae Asset Global Investments Co. Ltd. Purchases 5,800 Shares of Halozyme Therapeutics, Inc. $HALO

Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the third quarter, Holdings Channel.com reports. The firm acquired 5,800 shares of the biopharmaceutical company’s stock, valued at approximately $640,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Mather Group LLC. lifted its holdings in Halozyme Therapeutics by 48.9% during the third quarter. Mather Group LLC. now owns 414 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 136 shares in the last quarter. North Dakota State Investment Board increased its stake in shares of Halozyme Therapeutics by 4.3% during the third quarter. North Dakota State Investment Board now owns 3,598 shares of the biopharmaceutical company’s stock worth $397,000 after purchasing an additional 147 shares in the last quarter. CoreCap Advisors LLC increased its stake in shares of Halozyme Therapeutics by 98.0% during the third quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 150 shares in the last quarter. Fifth Third Wealth Advisors LLC increased its stake in shares of Halozyme Therapeutics by 3.5% during the third quarter. Fifth Third Wealth Advisors LLC now owns 4,515 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 151 shares in the last quarter. Finally, Twin Capital Management Inc. increased its stake in shares of Halozyme Therapeutics by 1.4% during the first quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 161 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HALO has been the subject of several research analyst reports. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $83.00 to $110.00 in a report on Friday, August 7th. HC Wainwright lifted their price objective on Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Finally, Citizens Jmp increased their target price on Halozyme Therapeutics from $93.00 to $149.00 and gave the company a “market outperform” rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $106.09.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $103.63 on Monday. The business has a fifty day moving average price of $115.19 and a 200 day moving average price of $84.73. The company has a debt-to-equity ratio of 13.50, a quick ratio of 3.60 and a current ratio of 3.88. The company has a market cap of $11.81 billion, a P/E ratio of 26.37, a P/E/G ratio of 0.39 and a beta of 0.92. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $134.00.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.09. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. The company had revenue of $492.97 million for the quarter, compared to analysts’ expectations of $491.63 million. During the same quarter in the previous year, the company posted $1.72 EPS. The firm’s quarterly revenue was up 39.1% on a year-over-year basis. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 8.32 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $109.40, for a total value of $2,188,000.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $83,995,132. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 5,230 shares of the business’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $108.54, for a total transaction of $567,664.20. Following the transaction, the director owned 53,609 shares in the company, valued at $5,818,720.86. The trade was a 8.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 124,226 shares of company stock valued at $13,370,893 over the last quarter. Company insiders own 2.50% of the company’s stock.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q3 revenue rose 39% year over year to $493 million and adjusted EPS of $2.39 beat estimates. Record royalty revenue increased 44% to $341 million. Halozyme also raised its 2026 revenue, royalty, EBITDA and adjusted EPS guidance. Q3 results and guidance
• Positive Sentiment: The FDA approved Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme’s ENHANZE technology, for certain patients with advanced head and neck cancer. The expanded use could support future royalties. FDA approval
• Positive Sentiment: Halozyme said its analysis of Medicare’s drug-price negotiation rule indicates zero to minimal impact on royalty revenue through at least 2035, easing a potential long-term concern. Medicare rule assessment
• Neutral Sentiment: Citizens JMP raised its price target to $149 and maintained an outperform rating, while Wells Fargo raised its target to $110 but kept an equal-weight rating—signaling differing views on further upside. Citizens JMP rating
• Negative Sentiment: Despite the earnings beat and higher guidance, reports noted a negative share reaction and questions around the guidance reset, suggesting results may not have met elevated investor expectations. The Merck patent dispute also remains an investor focus. Earnings reaction and guidance questions

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion.

Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Founded in 1998 and based in San Diego, California, Halozyme serves patients in multiple countries through its own commercial activities and, particularly for ENHANZE-enabled medicines, through its licensing partners.